Профиль

As I told @monicatorrr.bsky.social of @huffpost.com, "As [women] grow older and more mature in their careers, they lose some of the fear of speaking their mind. And certain men don’t like that." www.huffpost.com/entry/age-di...

Data Reveals An Infuriating Reason Women Over 40 Are Held Back At WorkA recent study exposes how insidious age discrimination is — and it should make you mad.www.huffpost.com

Summer's almost over 😎 #NephSky We know you've been waiting 🏖️ #NephJC Summer Book Club, 9/15/26 discussion! Salama Kassab was a pharmacy student in Syria. Now she helps the wounded who flood through the doors. Set amid the Syrian Revolution, a story of hope, love & possibility.

This is a superb educational episode Everything you wanted to know about C3G with Prof Carla Nester www.nephjc.com/freelyfilter... @freelyfiltered.bsky.social

Happy to share our 📜 "The Exam Room as Sanctuary - Caring for Undocumented Patients" Led by Dr. Miguel Linares at UCLA. www.nejm.org/doi/full/10....

A #NephJC short of the telitacicept trial from @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/sh... IMO the exciting part of the early signal of GFR stabilization - if this is recapitulated with atacicept and sibeprelimab - then we can truly say IgAN remission is here and achievable

NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial) — NephJCDoes Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?www.nephjc.com

In neonates with anhydramnios due to #fetal #kidney failure, serial #amnioinfusions before 26 weeks improved early survival outcomes, but many survivors required ongoing dialysis or kidney transplant and experienced significant morbidity. ja.ma/4wjibTR

To every transgender Minnesotan: you belong here. This decision does not change MN's law or our commitment to protecting LGBTQ+ people. Today's rulings remind us that defending the rule of law also means defending the rights and dignity of every person. I'll never stop fighting to do both. 8/8

It's time to start planning #NephMadness 2027! We would love your input as we start planning next year's tournament. Share your ideas: bit.ly/NM27Ideas @nephrosparks.bsky.social @annaburgner.bsky.social @kidneywars.bsky.social @catochita.bsky.social @ajkd.bsky.social

#NephMadness 2027: Call for Topic SuggestionsNephMadness 2026 is still fresh in our memories, but it’s already time to start thinking about NephMadness 2027! Which topics would you like to see in next year’s edition of the madness…bit.ly

We need to make sure this editorial goes viral Misguided Brushes of a Pen Continue to Dismantle and Destroy Biomedical Research in the United States: We Can No Longer Afford Complacency and Fear. We Must All Act Now! diabetesjournals.org/care/article...

The CEO of the American Diabetes Association is Charles D. "Chuck" Henderson. The Chief Medical and Scientific Officer is Rita Rastogi Kalyani. They should be ashamed of themselves.

We have multiple faculty positions open at UMN, one is research intensive, the other is primarily clinical. Feel free to reach out if interested or see the links below! umphysicians.wd1.myworkdayjobs.com/en-US/umpcar... umphysicians.wd1.myworkdayjobs.com/en-US/umpcar...

Infectious Diseases Physician - Assistant ProfessorProgram / Unit Description The Division of Infectious Diseases & International Medicine at the University of Minnesota is a globally recognized leader in clinical research and implementation scien...umphysicians.wd1.myworkdayjobs.com

Crazy happenings at the #ADA26 Cops show up, snatch papers and shove scientists out www.medpagetoday.com/special-repo...

Video: Police Tussle With Diabetes Experts at ADA MeetingResearchers told they could no longer attend the annual scientific sessionswww.medpagetoday.com

Rumor that the @amdiabetesassn.bsky.social is standing with …..the administration and denouncing their 5 colleagues (including the EiC of Diabetes Care) for violating ‘code of conduct’ Maybe the attendees should walk out. This is disgraceful from the ADA if true #ADA2026

And FIND CKD is live already on NEJM www.nejm.org/doi/full/10.... #ERA26

Finerenone in Persons with Chronic Kidney Disease without Diabetes | NEJMIn randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD)...www.nejm.org

Final GFR results from Atrasentan (ALIGN) in the Lancet Underwhelming to me - the Flozin + Atrasentan looks pretty good OTOH www.thelancet.com/journals/lan... Simulpubs from #ERA26

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trialAtrasentan reduced proteinuria and preserved kidney function after 2·5 years. This effect was present with or without concomitant SGLT2 inhibitor use. Atrasentan was well tolerated.www.thelancet.com

Short-term discontinuation due to adverse events was lowest for #ARB monotherapy and ARB plus calcium channel blocker regimens, compared with placebo. Combination therapies generally showed greater tolerability than monotherapies. ja.ma/436Phd6

What could possibly go wrong?

✨Exciting news #NephtSky The new #NephJC editorial interns are here! 📢Give them a follow and make them feel at home 👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇 www.nephjc.com/news/2025/6/...

NephJC Internship 2026-2027 — NephJCIntroducing NephJC’s brand new editorial internship class of 2026-2027www.nephjc.com

Even with federal grants largely restored, scientists say the Trump administration is still preventing those funds from reaching them. The consequences, they say, are already becoming clear.

Researchers say the Trump administration is finding new ways to punish scienceEven with federal grants largely restored, scientists say the Trump administration is still preventing those funds from reaching them. The consequences, they say, are already becoming clear.n.pr

An interim analysis of a phase 3 trial involving patients with IgA nephropathy showed that 39 weeks of treatment with telitacicept led to a greater reduction in the 24-hour urinary protein-to-creatinine ratio than placebo. Full TELIGAN trial results: https://nej.md/4uFpMLz